BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18006292)

  • 1. Multitasking by pVHL in tumour suppression.
    Frew IJ; Krek W
    Curr Opin Cell Biol; 2007 Dec; 19(6):685-90. PubMed ID: 18006292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
    Frew IJ; Smole Z; Thoma CR; Krek W
    Eur J Cancer; 2013 Jul; 49(10):2433-40. PubMed ID: 23541568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
    Nyhan MJ; O'Sullivan GC; McKenna SL
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.
    Kaelin WG
    Nat Rev Cancer; 2008 Nov; 8(11):865-73. PubMed ID: 18923434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
    Hergovich A; Lisztwan J; Barry R; Ballschmieter P; Krek W
    Nat Cell Biol; 2003 Jan; 5(1):64-70. PubMed ID: 12510195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
    Thoma CR; Frew IJ; Hoerner CR; Montani M; Moch H; Krek W
    Nat Cell Biol; 2007 May; 9(5):588-95. PubMed ID: 17450132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer.
    Minervini G; Pennuto M; Tosatto SCE
    Open Biol; 2020 Jul; 10(7):200109. PubMed ID: 32603638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.
    Kim WY; Safran M; Buckley MR; Ebert BL; Glickman J; Bosenberg M; Regan M; Kaelin WG
    EMBO J; 2006 Oct; 25(19):4650-62. PubMed ID: 16977322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.